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GENERAL INTRODUCTION 
Pseudorabies or Aujeszky's disease is caused by a herpesvirus and is 
considered one of the most economically important swine diseases in the 
world.lS,20 The virus causes systemic infection in a broad range of 
mammals, but swine are recognized as the primary host. Clinical 
characteristics of pseudorabies virus (PRV) infection in swine include: 
1) respiratory and central nervous system disturbances in growing pigs 
which lead to high mortality and reduction in growth rates; and 2) 
reproductive failure in pregnant sows and guilts. Clinical and sub-
clinical infection also lead to the establishment of latent infections. 
Ac=rding to a recent survey, 7S the annual loss attributed to 
pseudorabies in the United States of America has been estimated to exceed 
$ 30 million. The magnitude of this e=nomic loss has generated 
widespread support for the initiation of a campaign for the control and 
eventual eradication of pseudorabies. It is anticipated that subunit 
vaccines will play an important role in =ntrol and eradication 
programs.SI These vaccines will be particularly useful because their 
defined antigen =mposition will make it possible to identify virus 
infected vaccinated pigs by using non-vaccine viral proteins as 
diagnostic test antigens.so 
Recently, -an effective subunit vaccine has been developed at Iowa 
State University, Ames, IA.49,SO However, the cost of producing this 
vaccine may prevent it from being used by swine producers.Sl Enhancing 
2 
the immunogenecity of the vaccine will reduce the cost because less 
antigen per dose will be required. Recent studies have shown that 
' 
interleukin 2 can enhance the immune response of mice to vaccine 
antigen. 31 These findings suggest that IL-2 may have a similar effect in 
swine. The following thesis was conducted to test this hypothesis. 
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REVIEW OF THE LITERATURE 
Introduction 
Interleukin 2 (IL-2) is a T cell-secreted glycoprotein which 
regulates immune responses.1,34,61 It was first described in 1976 by 
Morgan et a1.41 who detected its presence in the supernatant of lectin-
stimulated human peripheral leukocyte cultures. Interleukin 2 was 
initially termed T cell growth factor (TCGF) because of its mitogenic 
effect on T cells.17,41,60 Recent studies utilizing recombinant IL-2 
(rIL-2)67 have demonstrated more definitive properties for this 
lymphokine. These properties include the ability to induce: a) the 
proliferation of lymphocytes,4,10,17,27,43,72,76 b) the differentiation 
of lymphocytes,16,19,21,30,33,45,65 and c) the production of additional 
lymphokines.14,29,54,69 As a result of these studies, there has been 
increasing interest in the use of IL-2 as an immune enhancing 
agent.2,6,7,23,26,31,57,59,64,69,71,72 The following review will first 
discuss the role that IL-2 plays in the immune response. Subsequently, 
the review will focus on the clinical application of IL-2. 
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Biochemical Characteristics of IL-2 
Human IL-2 is a glycosylated protein consisting of 133 amino acids67 
with a molecular weight of 15,ooo.13,20,61 The isoelectric point is 6.5. 
Interleukin 2 retains its biological activity following exposure to 700c 
for 15 min.12,18 It is also stable at a pH of 2.2 to lO.o.12,l8 
Role of IL-2 in the Immune Response 
Production of IL-2 
Pfizenmaier et al. 47 demonstrated that helper T lymphocytes (Th) are 
the primary source of IL-2. Production of IL-2 is believed to be 
initiated by at least two sequential events that take place on the 
surface of T 54,61 
h" Initially, antigen is processed and presented to Th 
by an antigen presenting cell (APC). This interaction is major 
histocompatibility complex (MHC) restricted. Subsequently the APC 
releases interleukin 1 (IL-1). Antigen and IL-1 are thought to interact 
with specific receptors present on the surface of Th.11,44,61 The 
signals that are generated from this interaction are transmitted by 
protein kinase C to the nucleus which results in IL-2 production 
following gene expression.9,32 
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The effect of IL-2 9!! specific lymphocyte populations 
Studies utilizing flow cytometry and radio-labeled IL-2 have 
revealed that IL-2 binds to specific receptors on the surface of T 
lymphocytes,3,37,46,55,56,66 B lymphocytes,5,37,40,46 NK cells45 and 
macrophages.22,28 To date no IL-2 receptors have been demonstrated on 
suppressor T lymphocytes. Several investigators37,46,55 have 
demonstrated by competitive binding studies that a high affinity receptor 
plays a significant role in cell activation. However, the high affinity 
receptors are expressed and stable only when the cells are activated. 
This requirement has workers to speculate that the mechanism of IL-2 
receptor expression may be regulated by other factors.21,66 Some 
investigators have proposed that the signal from the interaction of IL-2 
and its receptor is generated and transmitted by protein kinase C to the 
nucleus inducing cell activation.13 
Initially, many studies on lymphocyte-IL-2 interaction focused on 
cytotoxic T lymphocytes, (Tc).17,35,36,47 Lutz et al.38 demonstrated 
that both alloantigen and IL-2 were necessary to induce primary T to c 
proliferate and to activate their cytotoxic function. Later, Andrew et 
al. 3 reported similar observations and further demonstrated that removal 
of alloantigen resulted in the cessation of Tc proliferation and loss of 
cytotoxic activity even though rIL-2 was present. In contrast, Erard et 
a1.lO demonstrated that Tc proliferation and cytotoxic activation could 
be induced by rIL-2 alone. However, several groups of investigatorsl6,21 
have speculated from their experiments that antigen-induced monokines and 
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lyrnphokines other than IL-2 are necessary for the induction of Tc 
proliferation and the activation of cytotoxic activity. 
The role of IL-2 in the reactivation of Tc memory cells has been 
studied by Lefrancois et al., 36 who found that reactivation of small 
resting Tc memory cells occurs following exposure to either highly 
purified IL-2 or antigen. The finding of this work was supported by 
Hamuro,21 who restored cytotoxic activity to Tc memory cells by exposing 
them to human rIL-2. Hamuro's work was particularly valuable because the 
recombinant nature of the IL-2 used in his study eliminated the 
possibility that other co-factors were involved. Such co-factors could 
have been present in trace amounts in the non-recombinant IL-2 
preparations used by earlier workers. 
Studies have also demonstrated that IL-2 plays an important role in 
inducing cytotoxic activity of NK cells. Initially, activation of NK 
cells was thought to be due to the effect of gamma interferon (IFN-r) 
alone. 8, 74 Subsequently, Kuribayashi et al. 33 demonstrated that either 
IL-2 or IFN-r could independently activate cytotoxic NK cell activity. 
Svedersky et al.65 conducted a more definitive study using rIL-2 and 
demonstrated that IL-2 was a more effective NK cell activator than IFN-r. 
These workers and others30 reported that cytotoxic activity was directly 
proportional to the dose of IL-2. Grimm et a1. 19 described that IAK 
cells could also be activated by IL-2. Recent studies have suggested 
that IAK cells and NK cells might belong to same population because they 
are similarly activated by IL-2 and have similar surface markers.24,30 
Studies by several investigators with IL-2 have shown that this 
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lymphokine plays a critical role in the induction of clonal expansion of 
B cells and in their differentiation into innnunoglobulin secreting 
cells.29,39,40,42,43,46,72,76 Initially, Howard et ai.29 demonstrated 
that IL-2 induced Th to produce B cell growth factor (BCGF). These 
workers were not able to demonstrate that IL-2 had a direct effect on B 
cell proliferation. However, Zubler et a1.76 demonstrated that IL-2 
could directly induced proliferation of B cells which had been activated 
with lipopolysaccharide and anti-Ig M. The results reported by Zubler et 
al. 76 have subsequently been confirmed by other workers.5,40,42,43 
Although there is ample evidence that IL-2 directly induces B cell 
proliferation, there is no current evidence to indicate that IL-2 plays a 
role in the differentiation of B ce11.27 However, several 
investigators29,39,40, 43,54 have suggested that IL-2 has an indirect role 
in B cell differentiation because of its ability to induce Th to secrete 
IFN-r, BCGF, and B cell differentiation factors (BCDF). These 
lymphokines have been shown to directly affect B cell 
differentiation.27,43 
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Clinical Application 
Interleukin-2 has been evaluated in-vivo by several investigators to 
determine its effectiveness as a therapeutic and immune enhancing agent. 
Many of these studies have focused on the ability of IL-2 to enhance the 
anti-tumor property of IAK cells. This property was clearly 
characterized in mice by Hinuma et al.,26 who dem:>nstrated that daily 
doses of rIL-2 resulted in increased killer cell activity against a 
variety of tumor cells. This cytotoxic activity decreased to 
undetectable levels within 3 days of IL-2 withdrawal. The dose of IL-2 
required for sustaining this activity was extremely large and produced 
toxic side effects, which led these investigators to question the 
practicality of using IL-2 to treat human cancer patients. Rosenberg et 
a1. 57 have also used IL-2 to successfuly treat human cancer patients. 
These investigators were able to use lower doses of IL-2 and reduce toxic 
side effects by treating lymphocytes from cancer patients with IL-2 and 
tumor cells in-vitro. 
Enhancement of the in-vivo anti-tUm:>r activity of T has also been c 
dem:>nstrated by Hefeneider et al.,23 who reported that tumor specific T 
c 
cytotoxic activity was induced in mice by inoculating a mixture of 
allogeneic tumor cells and IL-2. Cheever et al.7 dem:>nstrated in a 
similar study that the degree of Tc activity was proportional to the dose 
of IL-2 inoculated. 
The use of IL-2 to reduce the severity of viral infection has also 
been studied. Rouse et al.59 were able to increase virus clearance in 
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herpes simplex virus type 1 (HSV-1) infected mice by treating these mice 
with IL-2 and IL-2 treated antigen-sensitized lynq?hocytes collected from 
the spleen of syngeneic mice. They were not able to deI!Onstrate enhanced 
virus clearance by treating mice with IL-2 alone. However, Weinberg et 
a1.71 repcrted that the use of IL-2 by itself did have an anti-viral 
effect. This effect was deI!Onstrated by challenging IL-2 treated and 
non-treated guinea pigs with HSV-2. Both infection rates and the 
severity of the clinical respcnse were significantly lower in the treated 
guinea pigs. These investigators did not speculate on the pcssible anti-
viral mechanisms that were enhanced. However, Rouse et a1.59 propcsed in 
their study that the I!Ost likely anti-viral mechanism affected was the 
cell-mediated innnune respcnse. 
One of the first studies to suggest that IL-2 could be used to 
enhance the immune respcnse of animals to vaccine antigen was conducted 
by Kawamura et a1.3l These workers repcrted that the incorpcration of 
rIL-2 with antigen in Freund's complete adjuvant induced higher antibody 
levels in mice than adjuvanted antigen alone. Recently Anderson and 
Urban2 repcrted that human rIL-2 enhanced vaccine immunity to Hemophilus 
pleulopneUI!Oniae in swine when IL-2 was given separately from the vaccine 
over five consecutive days beginning on the day of vaccination. Their 
conclusion was based only on clinical observations. 
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MATERIAIS AND MEI'HODS 
Medium and Reagents 
Cell growth medium (GM) consisted of Dulbecco's modified Eagle's 
minimum essential medium (MEM) with Earle's salts and supplemented with 5 
% fetal calf serum (FCS). Maintenance medium (MM) was GM with 2 % FCS. 
Hank's balanced salts solution (HBSS), without calcium and magnesium, was 
used for lymphocyte processing. Medium 199 containing 25 mM Hepes, L-
glutamine, and Earle's salts was supplemented with 15 % FCS. All media 
contained 100 units/ml of penicillin G, 100 ug/ml of streptomycin 
sulfate, 10 ug/ml of gentamycin sulfate and 1.65 ug/ml fungizone. 
Human recombinant interleukin 2 (rIL-2) was supplied in the 
lyophilized state by Cetus Corp, Emeryville, CA. It was rehydrated to 
stock concentration with 1.2 ml of sterile deionized double distilled 
water and extended to the desired concentration with 10 mM sodium 
phosphate buffer without potassium (pH 7.5), containing 0.01 % SDS. 
Reconstituted interleukin 2 was stored at 4°c and used within 10 h of 
preparation. The solubilized state of rIL-2 was verified by 
demonstrating the presence of protein in solution and failure to reduce 
optical density readings at 280 nm after centrifugation of the IL-2 
preparation at 50 K x g for 60 min. 
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Virus and Cells 
Virulent pseudorabies virus (PRV) strain Be was used for subunit 
vaccine preparation, antigen for lymphocyte blastogenesis assays and 
virus challenge studies. Virus was propagated in PK 15 cells for vaccine 
production ?fild in Madin-Darby bovine kidney (MDBK) cells for use in 
challenge studies and blastogenesis assays. 
Vaccine Preparation 
The pseudorabies virus subunit vaccine consisted of viral 
glycoproteins that were extracted from solubilized virus infected PK 15 
cells by lectin affinity chromatography as described-by Platt.49 In 
brief, PK 15 cells were inoculated with strain Be at a multiplicity of 
10. Virus infected cells were harvested 18 to 20 h post infection, 
washed 3 times with serum free medium and solubilized with 0.025 m 
tris/tricine (Tl') buffer pH 8.0, containing 1 % v/v triton-X 100. 
Solubilized glycoprotein was then extracted by lectin affinity 
chromatography using Lens culinaris agglutinin (I.CA) covalently linked to 
agarose beads. Glycoprotein was eluted from the lectin column with 1 % 
w/v mannose in Tl' buffer. The protein concentration was determined by 
the dye binding assay as described by Read and Northcote.52 Protein was 
diluted to desired concentration and suspended in Freund's incomplete 
adjuvant. 
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Serum Virus Neutralization Assay 
Serum virus neutralizing (SN) titers were determined by the 
microtiter serum neutralization test as described by Hill et a1.25 with 
modifications. In brief, serum samples were heat-inactivated at 560c for 
45 min. Duplicate serial two-fold dilutions were made with 50 ul of MEM 
in 96 well flat-bottomed microtiter plates. Subsequently, 300 TCID50 of 
virus suspended in 50 ul of MEM was placed into each well and incubated 
for 60 min. at 37°C. Following incubation, 4 x 104 MDBK cells contained 
in 150 ul of GM were added to each well and the preparations were 
incubated for 48 h at 37°c in a 5 % co2 humidified atmosphere. The cell-
virus preparations were then fixed with 10 % formalin and stained with 
crystal violet. Serum titers were expressed as the geometric mean (log2) 
of the reciprocal of the highest serum dilution that prevented CPE in 
duplicate wells. Positive and negative serums were run for each assay. 
Enzyme Linked IIlllllunosorbent Assay 
The enzyme linked iilllllunosorbent assay (ELISA) used in this study was 
a modification of the procedure described by Snyder and Erickson.62 Test 
and control antigens were produced by solubilizing virus infected and 
non-infected PK 15 cells with 0.025 M TT buffer, pH 8.0, containing 1 % 
v/v triton-X 100. Antigen preparations were optimally diluted in 0.02 M 
sodium carbonate/bicarbonate (CB) buffer, pH 9.6 and added at the rate of 
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100 ul to individual wells of Immulon I microtiter plates (Dynatech Lab. 
Inc., Chantilly, VA). The plates were incubated for 37°C and for at 
least 18 h at 40c. Unreacted sites in wells were blocked with 2 % 
gelatin in CB buffer for 1 h at 37°c. Plates were then washed with 0.01 
M phosphate buffered saline (PBS), pH 7.2 containing 0.05 % Tween 20 (WB) 
and stored at 40c until used. 
Test and control serums were diluted 1:20 in 0.05 M Tris buffer pH 
7.4 containing 150 mM sodium choride, 0.01 nM EIJI'A, 0.05 % Tween 20 and 
l. 0 % gelatin. One hundred ul of each diluted serum was added in 
duplicate to antigen-coated wells. The preparations were incubated 30 
min. at 37°C and washed eight times with WB and stained for 30 min. at 
37°C with 100 ul of optimally diluted goat anti-porcine lg G (H+L) 
conjugated to horseradish peroxidase (Kirkegaard & Perry Laboratories 
Inc., Gaithersburg, MD). All wells were again washed eight times with WB 
and dried. 
One hundred ul of enzyme substrate solution consisting of 0.05 % v/v 
hydrogen peroxide in 0.1 M citric acid disodium phosphate buffer, pH 5.0 
containing 0.034 % w/v 0-phenylene diamine was added to all wells. Color 
was allowed to develop in the dark at 25°c for 25 min. and stabilized 
with 50 ul of 4.5 M sulfuric acid. Individual absorbance values were 
determined with a Dynatech MR 580 ELISA Microplate reader equiped with a 
test filter wavelength of 490 nm and a reference filter wavelength of 450 
nm. The data were expressed as the mean of duplicate corrected optical 
density readings, which were calculated by subtracting the optical 
density (OD) of control antigen wells from the OD of test antigen wells. 
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Results of the above ELISA were confirmed with a commercially available 
ELISA (Agritech Inc., Portland, ME) at the Iowa State Veterinary 
Diagnostic Laboratory located at Iowa State University, Ames, IA. 
Lymphocyte Blastogenesis Assay 
Lymphocytes were isolated from citrated blood by extending 9 ml of 
blood to 20 ml by adding 0.01 M PBS, pH 7.2 heated to 37°c. Diluted 
blood was then carefully layered over 10 ml of Histopaque-1077 (Sigma 
Chemical Co., St. Louis, MO) contained in a 25 X 150 mm siliconized glass 
tube. The preparations were then centrifuged at 400 X g for 45 min. 
Lymphocytes were collected from the Histopaque-plasrna interphase into a 
15 X 125 mm plastic culture tube. The cells were washed with 5-10 ml of 
warmed HBSS and collected by low speed centrifugation at 250 X g for 10 
min. Residual red blood cells in the cell pellet were lysed by exposure 
to 0.87 % w/v annnoniurn chloride in distilled water for 5 min. 
Lymphocytes were washed twice with warmed HBSS and resuspended in Medium 
199 to adjust the cell concentration to 2.5 x 106/ml. 
Whole virus was used as test antigen in the lymphocyte blastogenesis 
assay. Virus was produced in PK 15 cells that were inoculated at a 
multiplicity of 5. Virus was harvested by 2 cycles of freeze-thawing 
when 100 % of cell rnonolayer showed CPE. The cell lysate was clarified 
by low speed centrifugation and heated at 56°c for 45 min. Heat-
inactivated virions were concentrated by ultracentrifugation at 50 K x g 
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for 120 min. The resulting pellet was resuspended to 1/10 of the 
original volume in serum-free Medium 199. The antigen preparation was 
aliquoted and stored at -700c until used. Control antigen was produced 
in identical manner from non-infected cells. Concanavarin A (Con A) (EY 
Laboratories Inc., San Mateo, CA) was used as lynphocyte mitogenic 
control. Concanavarin A was rehydrated in distilled water, filtered 
through a o. 22 um pore size membrane and stored at -10°c. 
The lynphocyte blastogenesis assay was a modification of the 
procedure described by Roth et al. 58 Two hundred ul of individual 
lynphocyte suspensions were dispensed into individual wells of a flat-
buttom 96 well culture plate and treated in triplicate with 25 ul of 
optimum concentrations of either test antigen, control antigen, Con A or 
medium. The preparations were incubated at 370c, in a 5 % co2 humidified 
atmosphere for 96 h and pulsed with 0.2 uCi of 3ii-thymidine (Amarsham 
Corp., Arlington Heights, IL) for 18 h. Lynphocytes from each well were 
harvested with a Cell Harvester (Flow Lab. Inc., Rockville, MD) onto 
glass fiber filter paper (Skatron Inc., Sterling, VA) and measured for 
beta emissions with a liquid scintillation counter. Mean counts per 
minutes (cpm) were determined for each sample and stimulation indexes 
(SI) were calculated by dividing the mean cpm induced by test antigen by 
the mean cpm induced by control antigen. 
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Experimental Design 
The effect of IL-2 as an immune enhancing agent in pigs was 
evaluated by =mparing the clinical and immune response of IL-2 treated 
and non-treated PRV subunit vaccinated pigs. Weanling, cross-bred pigs 
were randomly divided into 5 groups of 3 principals each. 'IWo groups 
received 2 high vaccine doses of 25 ug each given s.c. 3 weeks apart. 
The other two groups received 2 low vaccine doses of 5 ug each given in 
the same manner. A fifth group served as unvaccinated =ntrols. One 
high and one low vaccine dose group were treated two times with IL-2 
given s.c. at the rate of 105 units/kg for five consecutive days 
beginning on the day of each antigen inoculation.2 All pigs were housed 
together and challenged with 105.0 PFU of virus 3 weeks after the second 
vaccine inoculation. 
The clinical response of pigs was evaluated by comparing survival 
rates, weight responses and the anount of virus re=very from nasal 
cavities following virus challenge. Weight was monitored every other 
day, beginning on the day of challenge and continuing through day 14 post 
challenge (p.c.). Nasal swabs for virus assay were collected on the day 
of challenge and on days 2, 4, and 6 p.c. The cell-mediated immune 
response was evaluated by the lymphocyte blastogenesis assay 2 days 
before challenge, the day of challenge (day 0) and days 3, 5, 8, and 10 
p.c. Test =ntrol lynp'-ocytes were =llected on the same days from 2 
separately housed pigs which were not challenged with virus. The humoral 
immune response was evaluated by the ELISA, and the SN using serums 
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collected on the day of the first and second vaccine inoculation, 7 and 2 
days before virus challenge, and on days 0, 3, 5, 8, 10, 14, and 22 p.c. 
Daily SN titers and ELISA corrected OD readings of IL-2 treated and 
non-treated groups were independently compared for each vaccine dose by 
the least significant difference (ISD) procedure63 for: a) the pre 
challenge period extending from the day of the second vaccine inoculation 
(day -21) through the day of challenge (day O); and b) the anamnestic 
period between day 0 and 10. Cell-mediated immune responses of each 
treatment group were expressed as transformed (log10) stimulation indexes 
($I) and independently compared among treatment groups by Tukey's w 
procedure63 over three time periods: a) days -2 and O; b) days 3 and 5; 
c) days 8 and 10. The SI values were also analyzed between vaccinated 
and non-vaccinated groups by the ISD procedure over the same periods. 
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RESULTS 
The Effect of Recombinant Interleukin 2 on the Clinical Response of 
Vaccinates to Nasal Challenge with PRV 
No differences were observed in the clinical response of IL-2 
treated and non-treated vaccinated pigs. All 12 vaccinated pigs survived 
virus challenge (100 %) while only 2 of 3 non-vaccinated controls 
survived (67 %) • The weight response of treatment groups is summarized 
in Table 1 and illustrated in Figure 1. All treated and non-treated 
vaccinates gained weight during the first 2 days p.c. The mean daily 
gain during this period ranged from 0.35 to 0.95 kg. Thereafter 
vaccinated pigs lost weight during the next 4 days at a mean daily rate 
ranging from 0.55 to 0.90 kg. In contrast, the mean daily weight lost of 
non-vaccinated controls was 1.20 kg. Subsequently, all groups of 
vaccinates gained weight from day 6 through day 14 p.c. at mean daily 
rates rangimg from 0.70 to 1.10 kg. In contrast, non-vaccinated controls 
gained weight at a mean daily rate of 0.20 kg. 
Virus shedding patterns of IL-2 treated and non-treated pigs are 
summarized in Figure 2. No differences were observed between IL-2 
treated and non-treated vaccinated pigs. The maximum anount of virus was 
recovered from 11 out of 12 vaccinated pigs on day 4 p.c. The mean 
aIIOunt of virus recovered from all vaccine groups at this time ranged 
from 103.2 to 104.2 PFU. By day 6 p.c. the mean anount of virus 
19 
recovered from vaccinates decreased to less than 103.2 PFU. In contrast, 
the mean amount of virus recovered from non-vaccinated controls exceeded 
104.2 PFU on days 2, 4, and 6 p.c. 
The Effect of Recombinant Interleukin 2 on the Cell-mediated Immune (CMI) 
Response of Vaccinates to Nasal Challenge with PRV 
The CMI response as represented by transformed (log10) stimulation 
indexes (SI) of IL-2 treated and non-treated vaccinates to whole virus 
antigen is summarized in Table 2 and Figure 3. No differences were 
observed between the CMI response of IL-2 treated and non-treated 
vaccinated groups before and after virus challenge. However, significant 
differences were observed between vaccinated and non-vaccinated controls. 
The mean SI of all vaccinated groups on days -2 and 0 were 0.37 + 0.06 
compared to 0.10 ~ 0.03 for pigs of the non-vaccinated and test-control 
groups (P < 0.01). Significantly different mean SI responses of 1.02 ~ 
0.10 and 0.44 + 0.08 were observed for vaccinates and non-vccinated 
controls on days 3 and 5 p.c.( P < 0.01). However, significant 
differences between these groups were not observed on days 8 and 10. 
( 
Table L Weighta response of IL-2 treated or non-treated subunit-vaccinated pigs 
follo.-1ing nasal challenge 
Treatmentsc Mean weights Mean weight gain Mean daily weight gain 
on day 0 day 0-14 
(_:!: SE) 
day 0-2 day 2-6 day 6-14 
25 ug/dose 35.5 + 4.6 + 6.3 + 0.45 - 0.85 + LlO 
+ IL-2 
25 ug/dose 3LO + 3.9 + 7.3 + 0.70 - 0.55 +LOO 
5 ug/dose 27.2 + 2.8 + 3.9 + 0.95 - 0.90 + 0.70 
+ IL-2 
5 ug/dose 34.9 + 4.1 + 7.0 + 0.70 - 0.80 +LOO 
Control 35.4 + 4.4 - 4.1 + 0.30 - L20 + 0.20 
~eight expressed in kg. 
bPigs were nasally challenged with 105.o PFU of virulent PRV strain Be on day O. 
cPigs were vaccinated twice s.c. with lectin extracted PRV glycoproteins at 3 week 
intervals. Recombinant interleukin 2 (rIL-2) was given s.c. at a rate of 105 units/kg 
during two 5 day periods beginning on the day of the first and second vaccination. N=3 
for all groups. 
"' 0 
Figure 1. Weight resp0nse of IL-2 treated and non-treated sgb{f1it-
vaccinated pigs follaNing nasal challenge with 10 • PFU of 
virulent pseudorabies virus. Day 0 is the day of virus 
challenge. N=3 for all vaccinated groups. N=3 for control 
group through day 10, thereafter N=2 
22 
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Figure 2. The effect of IL-2 on the clearance of virus from the nasal 
cavitieg 8f subunit vaccinated pigs following nasal challenge 
with 10 • PFU of virulent pseudorabies virus. Day 0 is the 
day of virus challenge. N=3 for all groups 
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Table 2. Cell-mediated immune response of II.r-2 treated and non-treated subunit-vaccinated pigs 
pre and post nasal challenge with virulent pseudorabies virus (PRV) as determined by the 
lymphocyte blastogenesis assay 
Treatmentsa Mean stimulation index + SE (log10)b 
Day pre and post nasal challengec 
-2 0 3 5 8 10 
25 ug/dose + II.r-2 0.49 + 0.03 0.27 + 0.08 0.64 + 0.17 1.27 + 0.44 1.53 + 0.07 1.72 + 0.26 
25 ug/dose 0.37 + o.04 0.15 + 0.11 0.84 + 0.06 1.35 + 0.07 1. 31 + o. 30 1.12 + 0.19 
5 ug/dose + II.r-2 0.46 + 0.10 0.29 + 0.20 0.86 + 0.21 1.10 + 0.19 0.74 + 0.17 1.36 + 0.16 
5 ug/dose 0.54 + 0.25 0.31 + 0.15 0.22 + 0.08 1.05 + 0.45 0.64 + 0.18 1.68 + 0.09 
Control -0.06 + 0.03 0.16 + 0.08 0.10 + 0.07 0.63 + 0.09 0.41 + 0.18 1.35 + 0.12 
Test-control 0.12 + 0.03 0.17 + 0.06 0.19 + 0.19 0.08 + 0.04 0.11 0.08 + 0.09 
aPigs were vaccinated twice s.c. with lectin extracted.PRV glycoproteigs at 3 week 
intervals. Recombinant interleukin 2 (rllr-2) was given s.c. at a rate of 10 units/kg during two 
5 day periods beginning on the day of the first and second vaccination. N=3 for all groups except 
Test-control where N=2 for all days except day 8 when N=l. 
bStimulation index (SI) = cpm induced by viral antigen / cpm induced by =ntrol antigen. 
cAll groups except Test-=ntrol were challenged with 105.o PFU of virulent PRV strain Be. 
Test-=ntrols were separately housed. 
Figure 3. Cell-mediated immune response of IL-2 treated and
5
nsn-treated subunit-
vaccinated pigs following nasal challenge with 10 • PFU of virulent 
pseudorabies virus as determined by the lymphocyte blastogenesis assay. Day O 
is the day of virus challenge. N=3 for all groups except Test-control where N=2 
for all days except day 8 when N=l 
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The Effect of Recombinant Interleukin 2 on the Hun10ral Inmrune Response of 
Vaccinates to Nasal Challenge with PRV 
The hun10ral antibody response of IL-2 treated and non-treated 
vaccinated pigs was determined by the ELISA, and the SN assay. Results 
of these tests are srnmnarized in Tables·3, 4, 5 and illustrated in 
Figures 4, 5, 6, 7, 8 respectively. The mean SN titers of treated high 
and low vaccine dose groups were consistently greater than SN titers of 
non-treated pigs throughout the test period (Table 3). These values were 
only significantly different arrong high dose vaccinates during the pre-
challenge period (P < 0.05). 
The ELISA corrected OD values of IL-2 treated high and low dose 
vaccinates were also greater than the corresponding values of non-treated 
vaccinates throughout the test period (Tables 4 and 5). Highly 
significant differences were demonstrated between the treatment groups of 
high dose vaccinates by the commercial ELISA (P < o. 01). No significant 
differences were observed between treatment groups of low dose 
vaccinates. 
Table 3. Humeral antibody response of IL-2 treated and non-treated subunit-vaccinated pigs pre 
and post nasal challenge with virulent pseudorabies virus (PRV) as determined by the 
microtiter serum neutralization assay 
Treatments a Geometric mean±: SE (log2) 
Day pre and post nasal challengeb 
-21 -7 -2 0 3 5 8 10 14 22 
25 ug/dose + IL-2 o.oo 0.83 0.33 0.50 0.50 0.67 3.17 4.67 4.17 4.17 
+o.oo +o.17 +o.17 +o.oo +o.29 +o.33 +o.17 +o.17 +o.17 +o.17 
25 ug/dose o.oo o.oo o.oo o.oo o.oo o.oo 2.50 3.50 4.33 4.17 
+o.oo +o.oo +o.oo -l{).00 +o.oo +o.oo +o.50 +o.50 +o.17 +o.17 
5 ug/dose + IL-2 o.oo 0.13 o.oo o.oo o.oo o.oo 2.00 4.33 4.17 4.17 
+o.oo +o.oo +o.oo +o.oo +o.oo +o.oo +o.50 +o.44 +o.17 +o.17 
5 ug/dose o.oo 0.13 o.oo o.oo o.oo o.oo 1.50 3.33 3.50 3.67 
+o.oo +o.oo +o.oo +o.oo +o.oo +o.oo +o.29 +o.33 . +o.oo +o.33 
Control o.oo o.oo o.oo o.oo o.oo o.oo 0.33 1. 70 4.50c 4.50 
+o.oo +o.oo +o.oo +o.oo +o.oo +o.oo +o.17 +o.33 +o.oo +o.50 
~igs were vaccinated twice s.c. with lectin extracted PRV gly=proteigs
0
at 3 week 
intervals. Re=rnbinant interleukin 2 (rIL-2) was given s.c. at a rate of 10 • units/kg during 
two 5 day periods beginning on the day of the first and second vaccination. N=3 per group. 
bPigs were nasally challenged with 105•0 PFU of virulent PRV strain Be. 
cOne of 3 pigs died on day 11. 
Figure 4. Humeral antibody response of IL-2 treated and non-treated 
subunit-vaccinated pigs following nasal challenge with lOS.O 
PFU of virulent pseudorabies virus as determined by the 
microtiter serum neutralization assay. Day O is the day of 
virus challenge. N=3 for all vaccinated groups. N=3 for 
control group through day 10, thereafter N=2 
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Table 4. Humoral antibody response of IL-2 treated and non-treated subunit-vaccinated pigs pre 
and post nasal challenge with virulent pseudorabies virus (PRV) as determined by the 
enzyme-linked irrununosorbent assay 
Treatmentsa Mean corrected optical density (ODJb + SE 
Day pre and post nasal challenge with 105•0 PFU of virulent PRV strain Be 
-21 -7 -2 0 3 5 8 10 14 22 
25 ug/dose + IL-2 0.010 0.215 0.167 0.202 0.190 0.207 0.435 0.493 0.482 0.477 
+o.003 +o.012 +o.006 +o.020 +o.021 +o.009 +o.001 +o.022 +o.032 +o.029 
25 ug/dose 0.012 0.138 0.130 0.131 0.132 0.184 0.392 0.388 0.383 Q.422 
+o.005 +o.005 +o.017 +o.017 +o.018 +o.020 +o.028 +o.032 +o.050 +o.017 
5 ug/dose + IL-2 0.021 0.135 0.112 0.146 0.125 0.163 0.383 0.408 0.430 0.453 
+o.015 +o.041 +o.039 +o.030 +o.035 +o.030 +o.014 +o.018 +o.012 +o.021 
5 ug/dose 0.015 0.106 0.100 0.099 0.098 0.123 0.279 0.314 0.343 Q.369 
+o.008 +o.041 +o.044 +o.044 +o.041 +o.042 +o.035 +o.029 +o.019 +o.008 
aPigs were vaccinated twice s.c. with l~ctin extracted PRV glycoproteigs at 3 week 
intervals. Recombinant interleukin 2 (rIL-2) was given s.c. at a rate of 10 units/kg during two 
5 day periods beginning on the day of the first and second vaccination. N=3 for all groups. 
bcorrected optical density (OD) equals OD of serum plus test antigen minus OD of the same 
serum plus cell control antigen. Mean corrected OD + SE of 12 known negative serums was 0.001 + 
0.0005. 
w 
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Figure 5. Humoral antibody response of IL-2 treated and non-treated high 
do~e0subunit-vaccinated pigs following nasal challenge with 10 • PFU of virulent pseudorabies virus as determined by the 
enzyme-linked inununosorbent assay. ray O is the virus 
challenge day. N=3 for all groups 
Figure 6. Humoral antibody response of IL-2 treated and non-treated low 
do~e0subunit-vaccinated pigs following nasal challenge with 10 · PFU of virulent pseudorabies virus as determined by the 
enzyme-linked inununosorbent assay. ray O is the virus 
challenge day. N=3 for all groups 
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Table 5. Humoral antibody response of n.-2 treated and non-treated subunit-vaccinated pigs pre 
and post nasal challenge with virulent pseudorBbies virus (PRV) as determined by a 
commercial enzyme-linked immunosorbent assaya• 
Treatmentsc Mean corrected optical density (OD)d :!:: SE 
Day pre and post nasal challengee 
-21 -7 -2 0 3 5 8. 10 14 
25 ug/dose + IL-2 0.244 0.997 0.957 0.906 0.857 0.818 1.240 1.280 1.230 
+o.038 +o.021 +o.029 +o.050 +o.044 +o.014 +o.002 +o.071 +o.035 
25 ug/dose 0.165 o.569 0.638 0.527 0.408 o.539 1.170 1.070 1.140 
+o.063 +o.022 +o.050 +o. 045 +o.029 +o.055 +o.035 +o.037 +o.062 
5 ug/dose + IL-2 0.165 0.498 0.546 0.550 0.477 0.561 1.001 1.183 1.201 
+o.065 +o.200 +o.200 +o.200 +o.161 +o.129 +o. 013 +o.024 +o.036 
5 ug/dose 0.160 0.446 0.477 0.423 0.400 0.446 1.110 1.066 1.157 
+o.068 +o.204 +o.206 +o.193 +o.178 +o.168 +o~061 +o.041 +o.030 
Control 0.017 0.011 0.008 0.019 0.026 0.024 0.334 o.789 1.023 
+o.004 +o.006 +o.004 +o.011 +o.006 +o.065 +o.065 +o.052 +o.068 
aAgritech Inc., Portland, ME. 
bELISA assay was performed by Veterinary Diagnostic Laboratories, Iowa State University, 
Ames, IA. 
22 
1.340 
+o. 074 
1.190 
+o.030 
1.290 
+o. 010 
1.206 
+o.021 
1.161 
+o.140 
cPigs were vaccinated twice s.c. with lectin extracted PRV glycoproteigs at 3 week 
intervals. Recombinant interleukin 2 (rIL-2) was given s.c. at a rate of 10 units/kg during two 
5 day periods beginning on the day of the first and second vaccination. N=3 for all vaccinated 
.groups. N=3 for control group through day 10, thereafter N=2. 
dCorrected optical density (OD) equals OD of serum plus test antigen minus OD of the same 
serum plus cell control antigen. Mean corrected OD + SE of 21 known negative serums was 0.008 + 
0.004. 
ePigs were nasally challenged with 105•0 PFU of virulent PRV strain Be. 
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Figure 7. Humeral antibody response of IIr-2 treated and non-treated high 
doge0subunit-vaccinated pigs following nasal challenge with 10 • PFU of virulent pseudorabies virus as determined by a 
commercial enzyme-linked immunosorbent assay (Agritech Inc, 
Portland, ME). Day O is the virus challenge day. N=3 for all 
group 
Figure 8. Humeral antibody response of IIr-2 treated and non-treated low 
doge
0
subunit-vaccinated pigs following nasal challenge with 
10 ' PFU of virulent pseudorabies virus as determined by a 
commercial enzyme-linked immunosorbent assay (Agritech Inc, 
Portland, ME). Day 0 is the virus challenge day. N=3 for all 
group 
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DISCUSSION 
The preceding study was ccnducted to determine if human recombinant 
interleukin 2 (IL-2) could be used to enhance the immune response of pigs 
to a pseudorabies subunit vaccine. Results of this study showed that 
while the administration of IL-2 with vaccine antigen did not enhance the 
immune response of pigs to pseudorabies as determined by clinical signs 
and the cell-mediated immune (CMI) response (Tables land 2), it did 
induce ccnsistently higher SN and ELISA antibody titers (Tables 3, 4 and 
5). These differences were highly significant (P < 0.01) during the pre-
challenge and anamnestic periods among high dose vaccinates when measured 
by the commercial ELISA (Table 5 and Figure 7). The ability of the 
ccmmercial ELISA to detect statistically significant differences that 
were not revealed by the non-ccmmercial ELISA may have been due to 
quantitative differences in the ccmposition of the test antigen. The 
inability of the SN test to reveal differences as significant as those 
which were revealed by the ELISA may be due to the specificity of the 
test for neutralizing and not non-neutralizing antibodY. 
The higher antibody titers induced by IL-2 may be an indication that 
a stronger immune response was generated in IL-2 treated pigs. However, 
this suggestion is not supported by the clinical and CMI responses of 
treated and non-treated pigs. The inability to detect potential 
differences between groups by these parameters may have been due to the 
size of the vaccine dose used in the study. Earlier work in this 
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laboratory suggested that 10 ug of vaccine antigen approached the mininrum 
effective immunizing dose.48 Based on this finding, 5 ug of vaccine 
antigen was selected as a dose that would be small enough to demonstrate 
potentiation by IL-2. The use of smaller antigen doses might be required 
to demonstrate potential immune-enhancing effects of IL-2. Higher virus 
challenge doses may also be more effective in revealing differences in 
the clinical response of treated pigs. 
The increased antibody production observed in the current study was 
expected based on the work of Kawamura et a1.31 These workers were able 
to demonstrate increased levels of antibodies in mice that were 
inoculated with a mixture of IL-2 and antigen in Freund's complete 
adjuvant. The increased antibody production observed in the current 
study may have been due to clonal expansion of antigen-specific Th• which 
has been shown to be induced by IL-2.29,47,60,61 An expanded population 
of Th can indirectly cause an increase in the size of antigen-specific Tc 
and B lyrnphocyte populations through secreted lyrnphokines.29,39,40,43 
However, an expanded antigen-specific lymphocyte population was not 
reflected by the lyrnphocyte blastogenesis assay (Table 2) which measures 
the relative activity of Th, Tc, and B cells. The absence of differences 
in the stimulation indexes between IL-2 treated and non-treated 
vaccinates might be explained by the high degree of variability which is 
normally associated with the lymphocyte blastogenesis assay and the 
relatively small number of animals tested. It is also possible that the 
number of antigen-specific lymphocytes present in peripheral blood was 
too small to be detected. Activated lyrnphocytes may have been localized 
43 
in lymphoid organs. This hypothesis is supported by the work of Wittmann 
et a1.73 These investigators denonstrated in a PRV challenge experiment 
that lymphocytes derived from spleen or lymph nodes are more blastogenic 
to virus antigen than peripheral lymphocytes. 
Although the preceding study suggests that human recombinant IL-2 
may be a useful immune-enhancing agent in the pig, additional 
experimentation will have to be conducted in order to assess its 
effectiveness for this purpose. This experimentation will have to 
utilize: larger number of animals; a broader dose range of IL-2 and 
immunizing antigen; and more sensitive assays to evaluate the CMI 
response. 
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SUMMARY 
The effect of interleukin 2 (IL-2) as an iillllllllle enhancing agent in 
pigs was evaluated by coroparing the clinical and illlll\une response of IL-2 
treated and non-treated pseudorabies virus (PRV) subunit vaccinated pigs. 
Weanling, cross-bred pigs were raanomly divided into 5 groups of 3 
principles each. Two groups received 2 high vaccine doses of 25 ug each 
given s.c. 3 weeks apart. The other two groups received 2 low vaccine 
doses of 5 ug each given in the same manner. A fifth group served as 
unvaccinated controls. One high and one low vaccine dose group were 
treated two times with IL-2 given s.c. at the rate of 105 units/kg for 
five consecutive days beginning on the day of each antigen inoculation. 
All pigs were housed together and challenged with 105.0 PFU of virus 
three weeks after the second vaccine inoculation. Clinical responses 
were evaluated by determining the survival rates, weight responses, and 
virus shedding patterns. Humeral illlll\une responses were measured by the 
ELISA, and microtiter serum neutralization (SN) assay. Cell-mediated 
iillllllllle (CM!) responses were measured by the lymphocyte blastogenesis 
assay. No differences were detected in the clinical responses and CM! 
responses am:>ng treatment groups. However, the ELISA and SN antibody 
titers were consistently higher in IL-2 treated vaccinates. Differences 
determined by the ELISA am:ing high dose vaccinates were highly 
significant (P < 0.01). These results suggested that human recombinant 
IL-2 may be a useful iilllllUJ1e enhancing agent to PRV subunit vaccine. 
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